“The first studies affirm that the complete cycle of the 4 vaccines already approved remains protective against all Vocs – that is, the variants that are considered more risky – while the effectiveness that was highlighted after the first dose decreases “. The Higher Institute of Health (ISS) underlines this in an update of the Faq on its website.”As for the drugs in use and in experimentation, there is still no definitive evidence in one sense or another “. Some articles, Iss explains, indicate that some developing monoclonals may lose efficacy on their own, but mixes of 2 antibodies continue to work.
breaking latest news © Copyright ANSA